(redirected from Levodopa-Induced Dyskinesia)
Category filter:
LIDLow Impact Development
LIDLocal Improvement District
LIDLewica I Demokraci (Polish center-left political coalition)
LIDLow Incidence Disabilities (various locations)
LIDLead Independent Director (various companies)
LIDLoad Id
LIDLocal Id
LIDLogical Input Device
LIDLine Id
LIDLanguage Identification
LIDLink Interface Driver
LIDLost in the Desert (slang; Ft. Irwin, California)
LIDLiving in Denial
LIDLight Infantry Division
LIDLevodopa-Induced Dyskinesia (medical condition)
LIDLimited Ingredient Diet (Natural Balance pet food)
LIDLight Induced Degradation (solar cells)
LIDLeague for Industrial Democracy
LIDLog In Date (adoptions)
LIDLeadless Inverted Device
LIDLearning Improvement Days
LIDLogical Identifier
LIDLocal Injection and Detection (FOC)
LIDLicensed Interior Designer
LIDLoad Imbalance Detector
LIDLimited In Depth
LIDLaser Initiated Device
LIDLevy Improvement District
LIDLegislative Information Division
LIDLocal Interface Device (portable computer interface)
LIDLatinos in Development (Chicago, IL)
LIDLicense Information Document
LIDLast Issue Date
LIDLibrary Issue Document
LIDLaser Intrusion Device
LIDLeg In Disguise (airborne qualified soldier with less than 6 jumps)
LIDLinear Inertial Decoupler (Gemini Technologies, Inc.)
LIDLast Instrument Delivery
LIDLatest Induction Date
LIDLegionnaires in Doubt (Deathray song)
LIDLatch Insertion Delay
LIDLaser Image Display
LIDLead Identification Department
LIDLight Intensity Device
LIDLaser Illumination Detector
LIDLocal Information in Dorset (UK)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The increase in research and development expense is primarily related to the continued progress of ELEVATE, the Company's Phase 2 clinical study evaluating efficacy and safety of AV-101, its novel oral NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an add-on treatment (together with an FDA-approved oral antidepressant) for adults with major depressive disorder (MDD), several preclinical studies, including studies supporting AV-101's potential for treating neuropathic pain (NP) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease, and manufacturing activities involving AV-101 and the Company's two novel, clinical-stage neuroactive nasal spray candidates, PH94B for social anxiety disorder (SAD) and PH10 for MDD.
In addition, we remain on track to report data from our Phase 1b liver study of nalbuphine ER and initiate our Phase 2 study of nalbuphine ER for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease in the second half of 2019."
for intellectual property and data supporting the development of nalbuphine ER for levodopa-induced dyskinesia in patients with Parkinson's disease, the company said.
Its wholly-owned subsidiary has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression as well as adult attention deficit hyperactivity disorder, commonly known as ADHD.
is developing eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer's disease and adult attention deficit hyperactivity disorder (adult ADHD).
Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
Indeed, synaptic dysfunction is involved in a great number of neurological conditions, such as neurodegenerative diseases (Alzheimer's, Parkinson's, and Huntington's disease), dystonia, levodopa-induced dyskinesia, and ischemia [1-8], as well as neuropsychiatry conditions such as autism, schizophrenia, and major depression [9-15].
It has been shown that, among the four subtypes of AIMs in 6-OHDA-lesioned levodopa-treated rats, three subtypes, axial dystonia, limb dyskinesia, and orolingual dyskinesia, are equivalent to levodopa-induced dyskinesia (LID) in patients with PD [12, 16, 17].
Recent studies revealed that nondopaminergic systems such as adenosine, glutamatergic, adrenergic, serotoninergic, histaminic, and iron chelator pathways could include potential therapeutic targets for motor symptoms, including motor fluctuations, levodopa-induced dyskinesia, and gait disorders.
Levodopa-induced dyskinesia has been found to affect 30-35% of patients after just twenty-four months of levodopa exposure (17).
Santhera has global rights to fipamezole and has previously published promising data of its Phase IIb clinical trial in the treatment of levodopa-induced dyskinesia in Parkinson's disease.